IDRA insider filings
IDERA PHARMACEUTICALS, INC. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2023-01-12. Screen IDRA transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for IDRA between 2026-08-23 and 2026-11-21. The table below lists the most recent filings on record.
Recent insider filings — IDERA PHARMACEUTICALS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2023-01-12 | 4 | DOUGHERTY MICHAEL R — Director | Grant/award (A): 33,523 @ $0.44 | EDGAR |
| 2023-01-10 | 4 | Lim Bryant David — SVP AND GENERAL COUNSEL | Grant/award (A): 399,218 @ $0 · Tax withholding (F): 119,957 @ $0.71 | EDGAR |
| 2023-01-10 | 4 | Kirby John J. — CHIEF FINANCIAL OFFICER | Grant/award (A): 399,218 @ $0 · Tax withholding (F): 119,957 @ $0.71 | EDGAR |
| 2023-01-10 | 4 | JORDAN ANDREW R — CHIEF STRATEGY OFFICER | Grant/award (A): 261,718 @ $0 · Tax withholding (F): 73,940 @ $0.71 | EDGAR |
| 2022-10-05 | 4 | DOUGHERTY MICHAEL R — Director | Grant/award (A): 58,516 @ $0.37 | EDGAR |
| 2022-10-03 | 4 | NovaQuest Co-Investment Fund XV, L.P. — Director NQ POF V GP, Ltd. — Director | Other (J): 5 · Other (J): 1,343,547 (derivative) · Other (J): 14,115 (derivative) · Other (J): 14,115 (derivative) | EDGAR |
| 2022-09-30 | 4 | Taylor John Clayton — Chief Executive Officer, Director | Grant/award (A): 2,171,214 · Grant/award (A): 22,810 (derivative) | EDGAR |
| 2022-09-30 | 4 | Kraus Carl N — Chief Medical Officer | Grant/award (A): 651,364 (derivative) · Grant/award (A): 6,843 (derivative) · Grant/award (A): 6,843 (derivative) | EDGAR |
| 2022-09-30 | 4 | Salain Daniel — Chief Operating Officer | Grant/award (A): 2,171,214 · Grant/award (A): 22,810 (derivative) | EDGAR |
| 2022-09-30 | 4 | WOOTEN RONALD J — Director | Other (J): 5 · Other (J): 1,343,547 (derivative) · Other (J): 14,115 (derivative) · Other (J): 14,115 (derivative) | EDGAR |
| 2022-09-30 | 4 | JORDAN ANDREW R — Chief Strategy Officer | Grant/award (A): 651,364 · Grant/award (A): 6,843 (derivative) | EDGAR |
| 2022-09-26 | 4 | Pillar Invest Corp — 10% owner Pillar Partners Foundation, L.P. — 10% owner Pillar Pharmaceuticals 6, L.P. — 10% owner Umari Abude — 10% owner ZEIN YOUSSEF EL — 10% owner | Option exercise/expiry (X): 1,533,159 @ $0.01 · Option exercise/expiry (X): 1,533,159 (derivative) @ $0 | EDGAR |
| 2022-07-07 | 4 | Lim Bryant David — SVP AND GENERAL COUNSEL | Grant/award (A): 66,500 (derivative) @ $0 | EDGAR |
| 2022-07-07 | 4 | Kirby John J. — CHIEF FINANCIAL OFFICER | Grant/award (A): 66,500 (derivative) @ $0 | EDGAR |
| 2022-07-07 | 4 | SOLAND DANIEL B — CHIEF OPERATING OFFICER | Grant/award (A): 66,500 (derivative) @ $0 | EDGAR |
| 2022-07-07 | 4 | MILANO VINCENT — PRESIDENT AND CEO, Director | Grant/award (A): 124,000 (derivative) @ $0 | EDGAR |
| 2022-07-06 | 4 | DOUGHERTY MICHAEL R — Director | Grant/award (A): 50,086 @ $0.44 | EDGAR |
| 2022-06-27 | 4 | Goldberg Mark Alan — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2022-06-27 | 4 | Csimma Cristina — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2022-06-27 | 4 | GOWEN MAXINE — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2022-06-27 | 4 | SCHAFER CAROL — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2022-06-27 | 4 | GERAGHTY JAMES A — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2022-06-27 | 4 | DOUGHERTY MICHAEL R — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2022-04-05 | 4 | DOUGHERTY MICHAEL R — Director | Grant/award (A): 41,155 @ $0.54 | EDGAR |
| 2022-04-04 | 4 | Lim Bryant David — SVP AND GENERAL COUNSEL | Grant/award (A): 41,500 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | Kirby John J. — CHIEF FINANCIAL OFFICER | Grant/award (A): 41,500 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | SOLAND DANIEL B — CHIEF OPERATING OFFICER | Grant/award (A): 41,500 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | MILANO VINCENT — PRESIDENT AND CEO, Director | Grant/award (A): 99,000 (derivative) @ $0 | EDGAR |
| 2022-01-26 | 4 | Lim Bryant David — SVP AND GENERAL COUNSEL | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2022-01-26 | 4 | Kirby John J. — CHIEF FINANCIAL OFFICER | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2022-01-26 | 4 | SOLAND DANIEL B — CHIEF OPERATING OFFICER | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2022-01-26 | 4 | MILANO VINCENT — PRESIDENT AND CEO, Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2022-01-05 | 4 | DOUGHERTY MICHAEL R — Director | Grant/award (A): 37,062 @ $0.59 | EDGAR |
| 2021-12-21 | 4 | Kirby John J. — CHIEF FINANCIAL OFFICER | Purchase (P): 10,000 @ $0.61 | EDGAR |
| 2021-10-04 | 4 | DOUGHERTY MICHAEL R — Director | Grant/award (A): 21,229 @ $1.03 | EDGAR |
| 2021-07-12 | 4 | Lim Bryant David — SVP AND GENERAL COUNSEL | Grant/award (A): 66,500 (derivative) @ $0 | EDGAR |
| 2021-07-12 | 4 | Kirby John J. — CHIEF FINANCIAL OFFICER | Grant/award (A): 66,500 (derivative) @ $0 | EDGAR |
| 2021-07-12 | 4 | SOLAND DANIEL B — CHIEF OPERATING OFFICER | Grant/award (A): 66,500 (derivative) @ $0 | EDGAR |
| 2021-07-12 | 4 | MILANO VINCENT — PRESIDENT AND CEO, Director | Grant/award (A): 124,000 (derivative) @ $0 | EDGAR |
| 2021-06-21 | 4 | SOLAND DANIEL B — CHIEF OPERATING OFFICER | Purchase (P): 50,000 @ $1.19 | EDGAR |
| 2021-06-10 | 4 | Goldberg Mark Alan — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2021-06-10 | 4 | Csimma Cristina — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2021-06-10 | 4 | GOWEN MAXINE — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2021-06-10 | 4 | SCHAFER CAROL — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2021-06-10 | 4 | GERAGHTY JAMES A — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2021-06-10 | 4 | DOUGHERTY MICHAEL R — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2021-06-03 | 4 | DOUGHERTY MICHAEL R — Director | Purchase (P): 85,000 @ $1.19 | EDGAR |
| 2021-04-29 | 4/A | Pillar Invest Corp — 10% owner Pillar Partners Foundation, L.P. — 10% owner Pillar Pharmaceuticals 6, L.P. — 10% owner Umari Abude — 10% owner ZEIN YOUSSEF EL — 10% owner | Option exercise/expiry (X): 1,612,196 @ $0.01 · Option exercise/expiry (X): 883,613 @ $0.01 · Option exercise/expiry (X): 1,612,196 (derivative) @ $0.01 · Option exercise/expiry (X): 883,613 (derivative) @ $0.01 | EDGAR |
| 2021-04-05 | 4 | GERAGHTY JAMES A — Director | Grant/award (A): 14,773 @ $1.32 | EDGAR |
| 2021-04-05 | 4 | DOUGHERTY MICHAEL R — Director | Grant/award (A): 10,939 @ $1.32 | EDGAR |
Recent 8-K events — IDERA PHARMACEUTICALS, INC.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2023-08-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-07-21 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-07-11 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-30 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-05-04 | 8-K | ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events | EDGAR |
| 2023-03-30 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2023-02-06 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-02-03 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-01-18 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2023-01-17 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=IDRA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs